Characteristics of the patients and therapeutic procedures
| Patient No. . | Age . | Sex . | Diagnosis . | HLA I Recipient . | HLA I Donor . | Bone Marrow . | Conditioning . | Immunosuppression . | Day of Engraftment* . | GVHD Grade . | Chimerism† . | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| B . | T . | |||||||||||
| 1 | 5 | M | Pre-B ALL CR2 | A2,74 B44,B62 DRB1*0401,0701 | A2,29 B44,62 DRB1*0401,0701 | TCD | ATG, Cy FTBI | CsA, Mtx prednisolone | 18 | I | 63 | 63 |
| 2 | 39 | F | AML, CR3 | A1,32 B39,61 DRB1*1501,0404 | A1,32 B39,55 DRB1*1501,0404 | TCD | OKT3, Cy TBI | CsA, Mtx prednisolone | 22 | I | ND | ND |
| 3 | 8 | M | T-cell ALL CR2 | A3,25 B8,57 DRB1*0301,1401 | A2,25 B8,57 DRB1*0301,1401 | TCD | OKT3, Cy FTBI | CsA, Mtx | 22 | 0 | 42 | 104 |
| 4 | 6 | M | HLH | A30,32 B8,27 DRB1*0301,1101 | A32 B8,27 DRB1*0301,1101 | TCD | ATG, OKT3, Bu, Cy, VP16, TLI | CsA, Mtx prednisolone | 12 | 0 | 50 | ‡ |
| 5 | 13 | M | AML, CR1 | A3,25 B7,51 DRB1*1501,0404 | A3,25 B7,51 DRB1*1501,0408 | TCD | OKT3, Cy, FTBI | CsA, Mtx prednisolone | 17 | I-II | 501-153 | 501-153 |
| 6 | 1 | M | WAS | A1,2 B8,18 DRB1*0301 | A1,2 B8,18 DRB1*0301 | U | ATG, Bu, Cy | CsA, Mtx prednisolone | 18 | 0 | 661-154 | 661-154 |
| 7 | 14 | M | SAA | A2,32 B8,44 DRB1*0301,1301 | A2,32 B8,44 DRB1*0301,1301 | U | OKT3, Cy | CsA, Mtx prednisolone | 17 | 0 | ND | ND |
| 8 | 12 | F | ALL, CR3 | A1,2 B7,35 DRB1*1501,1104 | A1,2 B7,35 DRB1*1501,1104 | PBSC | OKT3, Cy, VP16, TBI | CsA, Mtx prednisolone | 11 | I | ND | ND |
| 9 | 7 | F | THAL | A2,32 B55,35 DRB1*1104,1401 | A2,32 B55,35 DRB1*1104,1401 | U | ATG, Bu, Cy | CsA, Mtx | 20 | I | ND | ND |
| Patient No. . | Age . | Sex . | Diagnosis . | HLA I Recipient . | HLA I Donor . | Bone Marrow . | Conditioning . | Immunosuppression . | Day of Engraftment* . | GVHD Grade . | Chimerism† . | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| B . | T . | |||||||||||
| 1 | 5 | M | Pre-B ALL CR2 | A2,74 B44,B62 DRB1*0401,0701 | A2,29 B44,62 DRB1*0401,0701 | TCD | ATG, Cy FTBI | CsA, Mtx prednisolone | 18 | I | 63 | 63 |
| 2 | 39 | F | AML, CR3 | A1,32 B39,61 DRB1*1501,0404 | A1,32 B39,55 DRB1*1501,0404 | TCD | OKT3, Cy TBI | CsA, Mtx prednisolone | 22 | I | ND | ND |
| 3 | 8 | M | T-cell ALL CR2 | A3,25 B8,57 DRB1*0301,1401 | A2,25 B8,57 DRB1*0301,1401 | TCD | OKT3, Cy FTBI | CsA, Mtx | 22 | 0 | 42 | 104 |
| 4 | 6 | M | HLH | A30,32 B8,27 DRB1*0301,1101 | A32 B8,27 DRB1*0301,1101 | TCD | ATG, OKT3, Bu, Cy, VP16, TLI | CsA, Mtx prednisolone | 12 | 0 | 50 | ‡ |
| 5 | 13 | M | AML, CR1 | A3,25 B7,51 DRB1*1501,0404 | A3,25 B7,51 DRB1*1501,0408 | TCD | OKT3, Cy, FTBI | CsA, Mtx prednisolone | 17 | I-II | 501-153 | 501-153 |
| 6 | 1 | M | WAS | A1,2 B8,18 DRB1*0301 | A1,2 B8,18 DRB1*0301 | U | ATG, Bu, Cy | CsA, Mtx prednisolone | 18 | 0 | 661-154 | 661-154 |
| 7 | 14 | M | SAA | A2,32 B8,44 DRB1*0301,1301 | A2,32 B8,44 DRB1*0301,1301 | U | OKT3, Cy | CsA, Mtx prednisolone | 17 | 0 | ND | ND |
| 8 | 12 | F | ALL, CR3 | A1,2 B7,35 DRB1*1501,1104 | A1,2 B7,35 DRB1*1501,1104 | PBSC | OKT3, Cy, VP16, TBI | CsA, Mtx prednisolone | 11 | I | ND | ND |
| 9 | 7 | F | THAL | A2,32 B55,35 DRB1*1104,1401 | A2,32 B55,35 DRB1*1104,1401 | U | ATG, Bu, Cy | CsA, Mtx | 20 | I | ND | ND |
GVHD indicates graft-versus-host disease; ALL indicates acute lymphatic leukemia; TCD indicates T-cell[en]depleted bone marrow; ATG indicates antithymocyte globulin; Cy indicates cyclophosphamide; FTBI indicates fractionated total-body irradiation; CsA indicates cyclosporin A; Mtx indicates methotrexate; AML indicates acute myeloid leukemia; TBI indicates total-body irradiation; ND indicates not done; HLH indicates hemophagocytic lymphohistiocytosis; Bu indicates busulfan; VP16 indicates etoposide; TLI indicates total lymph node irradiation (2 Gy for 4 consecutive days); WAS indicates Wiskott-Aldrich syndrome; U indicates unmanipulated bone marrow; SAA indicates severe aplastic anemia; PBSC indicates peripheral blood stem cells; THAL indicates thalassemia.
Days after BMT.
Days after BMT when 100% of the indicated cell subpopulation was found to be of donor origin.
The T cells of the patients were predominantly of recipient origin during the entire period of observation.
Recipient B and T cells were detected again in this patient 2 months later.
The first chimerism test was performed at the indicated time.